Earlier this month, the U.S. biopharma industry hit yet another recent major milestone with the market launch of Novartis/Sandoz’s Zarxio—the first-ever biosimilar drug to get a regulatory green light in this country.
This launch is just one part of what’s already shaping out to be tranformative year for the biotech and pharmaceutical sectors. From a record pace of drug approvals, to a frenzied M&A environment, to leadership changes in the FDA and regulatory overhauls of the American drug approval scheme, and deep controversies over the pricing of medications, the currents of change are shifting the trajectory of U.S. healthcare at large and the biopharma industry in particular.
Hey, check out all the research scientist jobs. Post your resume today!
